Spots Global Cancer Trial Database for recurrent uterine corpus cancer

Every month we try and update this database with for recurrent uterine corpus cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer	NCT02728258	Endometrial End... Endometrial Mix... Endometrial Ser... Endometrial Und... Metastatic Endo... Recurrent Uteri...	Copanlisib Laboratory Biom...	18 Years -	NRG Oncology
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer	NCT01935934	Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Ser... Metastatic Endo... Recurrent Uteri... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri... Uterine Corpus ...	Cabozantinib S-... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer	NCT03348631	Recurrent Endom... Recurrent Ovari... Recurrent Ovari... Recurrent Ovari... Recurrent Uteri...	Computed Tomogr... Magnetic Resona... Tazemetostat	18 Years -	National Cancer Institute (NCI)
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	NCT02142803	Adult Glioblast... Endometrial Cle... Endometrial Ser... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Solid Neoplasm Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Bevacizumab Laboratory Biom... Pharmacological... Sapanisertib	18 Years -	National Cancer Institute (NCI)
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer	NCT02059265	Endometrial Cle... Ovarian Clear C... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri...	Dasatinib Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors	NCT02142803	Adult Glioblast... Endometrial Cle... Endometrial Ser... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Serous ... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri... Solid Neoplasm Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar...	Bevacizumab Laboratory Biom... Pharmacological... Sapanisertib	18 Years -	National Cancer Institute (NCI)
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer	NCT01935973	Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Ser... Endometrial Und... Recurrent Uteri...	Laboratory Biom... Trametinib Uprosertib	18 Years -	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer	NCT02059265	Endometrial Cle... Ovarian Clear C... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Recurrent Uteri...	Dasatinib Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer	NCT01935934	Endometrial Ade... Endometrial Cle... Endometrial Mix... Endometrial Ser... Metastatic Endo... Recurrent Uteri... Stage IV Uterin... Stage IVA Uteri... Stage IVB Uteri... Uterine Corpus ...	Cabozantinib S-... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer	NCT02728258	Endometrial End... Endometrial Mix... Endometrial Ser... Endometrial Und... Metastatic Endo... Recurrent Uteri...	Copanlisib Laboratory Biom...	18 Years -	NRG Oncology
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer	NCT00492778	Endometrial End... Endometrial Muc... Endometrial Squ... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Uteri...	3-Dimensional C... Cisplatin Intensity-Modul... Internal Radiat...	-	GOG Foundation
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer	NCT00977574	Endometrial Ade... Endometrial Ade... Endometrial Cle... Endometrial Ser... Recurrent Uteri... Stage IIIA Uter... Stage IIIB Uter... Stage IIIC Uter... Stage IVA Uteri... Stage IVB Uteri...	Bevacizumab Carboplatin Ixabepilone Laboratory Biom... Paclitaxel Temsirolimus	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: